arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

NewAmsterdam Pharma Co N.V.

NAMS

$22.66 ▼ -0.68 (-2.91%) at close

6 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

NewAmsterdam Pharma Co N.V. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B

Dividend Yield —

Revenue Growth -50.6% ↘

Op. Margin None

ROIC -26.1% ↘

FCF / Share $-1.25 ↗

Trailing P/E —

Price / Book 3.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$22.50M

↓ -50.6% —

Net Income Profit after all expenses

$-203.82M

↑ +15.6% —

Operating Margin Operating profit as % of sales

-386.9%

↓ -11070.5% —

FCF / Share Free cash flow per share

$-1.25

↑ +25.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	-50.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-733%)	223.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2692%)	-86.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1178%)	—	—	—
EPS Growth YoY (%)	32.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-19.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-80.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	68.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	15.6% Good ↑ Good Improving Year-over-year change in net income	-36.5% Weak ↑ Weak Improving Year-over-year change in net income	-681.7% Weak Weak Year-over-year change in net income	45.8% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	25.7% Excellent Excellent Year-over-year change in free cash flow	2.2% Caution Caution Year-over-year change in free cash flow	N/M	N/M	—	—
Revenue CAGR 3Y (%)	-39.7% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	—	-386.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2679%)	—	-3.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-123%)	—	—
Effective Tax Rate (%) (%)	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	—	—	—	-22.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-284%)	—	—
FCF Margin (%) (%)	—	-348.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	10.4% Fair Fair Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.73x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-0.47x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-26.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-0.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	24.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-29.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-52.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-0.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-29.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-299%)	-31.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-313%)	-61.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-509%)	-5.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-135%)	36.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+145%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	—	—	—	-12.39x Weak Weak Operating income divided by interest expense Optimal: > 5x	-85.10x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-490.00M	$-771.74M	$-340.45M	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.19	$0.48	$0.17	$5.41	—	—
Basic EPS, GAAP (USD)	$-1.72	$-2.56	$-2.15	$-1.19	$-3.81	—
Free Cash Flow per Share (USD)	$-1.25	$-1.68	$-1.72	$0.56	$-2.69	—
Book Value per Share (USD)	$5.97	$7.01	$3.50	$11.86	$-10.37	—
Tangible Book Value per Share (USD)	$5.97	$7.01	$3.50	$11.86	$-10.37	—
Basic Weighted Avg Shares (shares)	118.42M	94.36M	82.16M	18.97M	10.98M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$589.91M	$756.50M	$296.89M	$441.92M	—	—
Total Equity (USD)	$683.43M	$757.50M	$288.39M	$430.07M	$-113.82M	$-73.03M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$22.50M	$45.56M	$14.09M	$102.69M	—	—
Depreciation Expense (USD)	$220.00K	$113.00K	$49.00K	$9.00K	$5.00K	—
Net Income, GAAP (USD)	$-203.82M	$-241.60M	$-176.94M	$-22.63M	$-41.78M	—
Operating Cash Flow (USD)	$-147.78M	$-158.56M	$-141.22M	$10.66M	$-29.51M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 17 quarters

NewAmsterdam Pharma Co N.V.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NAMS with peers